Geisinger Medical Laboratories Test Catalog
SYPHILIS ANTIBODY SCREEN WITH REFLEX TO RPR |
||
Geisinger Epic Procedure Code: LAB3111
Geisinger Epic ID: 38734
|
||
SPECIMEN COLLECTION |
||
Specimen type: |
Serum | |
Preferred collection container: |
||
Specimen required: |
One full 3.5 mL gold-top serum separator tube (preferred). | |
SPECIMEN PROCESSING |
||
Specimen processing instructions: |
Allow to clot. Centrifuge and submit one full 3.5 mL gold-top serum separator tube. | |
Transport temperature: |
Refrigerated | |
Specimen stability: |
5 days 2-8°C. | |
Rejection criteria: |
Specimen will be rejected if stability limit has been exceeded or if specimen is hemolyzed, lipemic or icteric. | |
TEST DETAILS |
||
Reference interval: |
Nonreactive. | |
CPT code(s): |
86780 | |
Note: The billing party has sole responsibility for CPT coding. Any questions regarding coding should be directed to the payer being billed. The CPT codes provided by GML are based on AMA guidelines and are for informational purposes only. | ||
Test includes: |
Qualitative detection of antibodies to Treponema pallidum (screening) by chemiluminescence, with reflex to RPR and Treponemal pallidum particle agglutination when appropriate. If the qualitative T. pallidum antibody result is negative, the testing is complete. If the qualitative detection of antibodies is positive, then a quantitative RPR will be performed. If the RPR is positive, the patient has active syphilis. If the RPR is negative, a Treponemal pallidum particle agglutination assay will be performed. If the T. pallidum particle agglutination is positive, the patient had a probable past syphilis infection. If the Treponemal pallidum is negative, the patient likely does not have syphilis. | |
Methodology: |
Chemiluminescence Agglutination |
|
Synonyms: |
SYPPRO
|
|
Clinical significance: |
Useful for aiding in the diagnosis of recent or past Treponema pallidum infection and for routine prenantal screening. This test is not useful for diagnosis of congenital syphilis or for monitoring response to treatment. | |
Doctoral Director(s:) |
Hoi-Ying Elsie Yu PhD, DABCC, FADLM | |
Review Date: | 12/13/2022 |